The estimated Net Worth of Omid Farokhzad is at least $106 Million dollars as of 7 March 2024. Dr Farokhzad owns over 52,857 units of Seer stock worth over $2,312,419 and over the last 8 years he sold SEER stock worth over $102,862,033. In addition, he makes $972,082 as CEO & Chair of the Board of Directors at Seer.
Dr has made over 13 trades of the Seer stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 52,857 units of SEER stock worth $107,300 on 7 March 2024.
The largest trade he's ever made was selling 1,089,279 units of Seer stock on 3 December 2020 worth over $69,877,248. On average, Dr trades about 114,741 units every 106 days since 2016. As of 7 March 2024 he still owns at least 1,436,285 units of Seer stock.
You can see the complete history of Dr Farokhzad stock trades at the bottom of the page.
Dr. Omid C. Farokhzad Ph.D., M.D. is the CEO & Chair of the Board of Directors at Seer.
As the CEO & Chair of the Board of Directors of Seer, the total compensation of Dr D at Seer is $972,082. There are no executives at Seer getting paid more.
Dr D is 51, he's been the CEO & Chair of the Board of Directors of Seer since . There are 3 older and 1 younger executives at Seer. The oldest executive at Seer, Inc. is David R. Horn, 53, who is the Exec. VP & Chief Financial Officer.
Omid's mailing address filed with the SEC is C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY, CA, 94065.
Over the last 7 years, insiders at Seer have traded over $150,878,393 worth of Seer stock and bought 1,798,420 units worth $33,507,980 . The most active insiders traders include Omid Farokhzad, Terrance Mcguire, and Growth Fund Limited Partner.... On average, Seer executives and independent directors trade stock every 60 days with the average trade being worth of $227,813. The most recent stock trade was executed by Dipchand Nishar on 14 June 2024, trading 12,109 units of SEER stock currently worth $21,554.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Seer executives and other stock owners filed with the SEC include: